SK Bioscience picks lead manager to go public
SEOUL, July 26 (Yonhap) -- South Korean vaccine maker SK Bioscience Co. said Sunday it has tapped NH Investment Securities Co. as the lead manager and Korea Investment Co. as the co-lead manager to sell its shares on the Seoul bourse.
"We have been pushing ahead with a plan to sell our shares on the Seoul bourse by 2021 to raise money for the expansion of our business and additional growth," the company said.
SK Bioscience was spun off from pharmaceutical company SK Chemicals of the country's third-largest conglomerate SK in July 2018.
The vaccine maker has been developing a vaccine to treat new coronavirus infections.
ksnam@yna.co.kr
(END)
-
(Movie Review) 'Troll Factory' navigates blurred line between fake, real with anticlimactic finale
-
Police officer admits to leaking investigation report into late actor Lee Sun-kyun
-
'Parasyte: The Grey' adapts Japanese alien invasion manga to Korean setting
-
S. Korea, U.S. launch task force to block N. Korea's nuclear, missile programs
-
N. Korean leader sends condolences to Putin over Russian concert hall shooting
-
(Movie Review) 'Troll Factory' navigates blurred line between fake, real with anticlimactic finale
-
'Parasyte: The Grey' adapts Japanese alien invasion manga to Korean setting
-
Police officer admits to leaking investigation report into late actor Lee Sun-kyun
-
Congenital diseases of children born from mothers working at Samsung recognized as industrial accidents
-
N. Korean leader sends condolences to Putin over Russian concert hall shooting
-
S. Korea, U.S. launch task force to block N. Korea's nuclear, missile programs
-
Unification minister slams N. Korea's abduction, detention of S. Koreans as inhumane
-
(LEAD) S. Korea, U.S. launch task force to block N. Korea's nuclear, missile programs
-
Major hospitals in emergency mode amid huge losses over doctors' walkout
-
Seoul bus drivers go on general strike